The need for a renewable source of erythro-relation to the evolution of renal replacement treatment. Haemodialysis for end
Review of initial clinical studies
Once the pilot studies were complete, a number of multicentre trials was performed. Reassuringly, the doses of r-HuEPO required to reverse anaemia and to maintain the haemoglobin concentrations were found to be similar in the USA and Europe. It was shown in several hundred patients [3] [4] [5] that the intravenous (i.v.) administration of different preparations of r-HuEPO at doses of approximately 200 IU/kg/week would increase the haemoglobin concentration to between 10 and 12 g/dl in >90% of subjects.
Haematological effects of r-HuEPO
In normal subjects the relationship between erythropoietin secretion and erythropoiesis is beautifully bal- Fig. 3 . The lineage of precursors leading from the stem cell to the anced, with red cell production sustained at the correct erythropoietin-sensitive and -dependent erythroid precursors and the growth factors acting upon them. EPO has its chief effect on rate to replace red cell loss ( Figure 2 ). The effect of sustaining the cells derived from the CFU-E. SCF=stem cell factor; EPO on the erythroid marrow is mediated following IL=interleukin; IGF-1=insulin-like growth factor 1; GM-CSF= binding to specific receptors on erythroid precursors granulocyte-macrophage colony-stimulating factor; CFU-GEMM= (intermediate-stage erythroid burst-forming units or granulocyte, erythroid, monocyte megakaryocyte colony-forming unit; CFU-MK=megakaryocyte colony-forming unit; CFU-GM= BFU-E and the erythroid colony-forming unit or granulocyte-macrophage colony-forming unit; CFU-E=erythroid CFU-E) that have already differentiated from pluripocolony-forming unit; BFU-E=erythroid burst-forming unit; EPO= tential stem cells (see Figure 3 ). Differentiation to this erythropoietin. For a more detailed description see Sieff and stage is not dependent on EPO. This has been shown Nathan [35] . by Wu et al. (1995) , who produced 'knockout' mice that lacked either the EPO or the EPO receptor genes preventing apoptosis and thereby allowing red cell [6 ] . Mice with either mutation were incapable of precursors to reach a stage at which they will inevitably erythropoiesis but committed CFU-E and BFU-E were mature into red cells [7] . present in the foetal livers. Thus, the expression of the As expected, the erythrokinetic studies performed receptor is itself an essential part of the mechanism by on the first dialysis patients treated with r-HuEPO which erythropoiesis is controlled. That the presence showed that the total red cell volume was below normal of EPO is an absolute requirement for erythropoiesis before treatment and increased after treatment. These is obvious; however the mechanism by which this route increases in red cell volume were accompanied by of differentiation and maturation is favoured is not. It reciprocal changes in plasma volume, so that blood may act as no more than a permissive survival factor, volume was barely changed. Red cell survival in nontransfused patients was only modestly shortened before treatment and was not altered by treatment. In transfusion-dependent patients, red cell survival was much shorter than normal, but this could be explained by the shorter survival of the transfused cells. The erythron transferrin uptakes ( ETUs), an accurate measure of erythroid marrow activity, were subnormal before treatment, and an overall twofold increase was observed after treatment was stabilized [8] .
Studies of the response of bone marrow erythroid progenitors to r-HuEPO treatment showed that after treatment, the number of bone marrow BFU-E had fallen to a mean of 24% of pre-treatment values, but there was no significant change in the number of CFU-E. The surprising decrease in BFU-E could be explained by depletion of this compartment by EPO- Fig. 2 . The balance between red cell production and destruction driven maturation to CFU-E without a commensurate allows the maintenance of a stable red cell mass. The shaded circles indicate the ways in which the components of this balance can be replenishment from the pluripotential stem cell pool. measured. ETU=erythron transferrin uptake; TFR=transferrin The failure to change the numbers of CFU-E would receptor protein (measurements of the rate of erythropoiesis); have to be explained by self-renewal and replenishment RIA=radio-immunoassay (for EPO); 51Cr=Chromium 51 labelling from the BFU-E, keeping the size of this compartment of erythrocytes used for measurement of the red cell mass and the rate of red cell destruction or loss. 
Route of administration Secondary benefits
The best marker of benefit of the introduction of The i.v. route was chosen as a matter of convenience r-HuEPO to clinical practice is the reduction in need and in ignorance of the pharmacodynamics of for regular blood transfusion [17] . The improvement r-HuEPO. What is the best route? Continuous ambuin symptoms attributable to anaemia is unequivocal latory peritoneal dialysis (CAPD) and pre-dialysis and was confirmed in a Canadian randomized, plapatients have little choice-subcutaneous (s.c.) admincebo-controlled study [18] , among others [19] . istration is the only practicable route-but haemodiThere are a number of secondary benefits to removalysis patients do have the i.v. option. Pharmacokinetic ing or ameliorating anaemia in dialysis patients. The studies showed that administration of r-HuEPO by cardiovascular system is the chief beneficiary, providing thrice-weekly i.v. pulses would saturate the EPO recepthe blood pressure is controlled. Improved oxygen tors but, because the half-life of r-HuEPO in plasma delivery reduces the incidence and severity of angina is approximately 8 hours, the concentration would fall and improves exercise capacity. There are reductions to baseline levels before the next scheduled administrain left ventricular mass and dimensions, which may tion. Subcutaneous administration of r-HuEPO results have implications for long-term survival. in a prolonged elevation of the plasma EPO concentra-
The haemostatic defect of anaemia is improved by tion, which should achieve a greater effect on erythroraising the haematocrit. This is usually a benefit but poiesis. By 1991, 11 of 15 reports comparing both may contribute to thrombosis of faltering vascular routes of administration had concluded that the latter access. There are also reports of improvement in sexual allowed lower maintenance doses. Since then three function, the immune system and pruritus [reviewed prospective, randomized, comparative trials have been in 20]. performed, yet the matter remains unresolved. Muirhead et al. found that the target haemoglobin was reached more rapidly in patients receiving r-HuEPO Audit of current usage s.c. but, although the doses at the time of stabilization and at 24-week follow-up were lower, the difference Estimates of the likely numbers of patients who would from the i.v. group at this latter time point was not benefit from r-HuEPO were made for the Oxford statistically significant [10] . Hö rl found that switching Renal Unit in 1988, based on the distribution of patients maintained on i.v. r-HuEPO to thrice weekly haemoglobin concentrations in 225 haemodialysis s.c. administration allowed a 32% reduction in mean patients, 69 CAPD patients and 88 pre-dialysis patients dose but daily s.c. administration allowed no greater with plasma creatinines >350 mmol/l. What has hapdose reduction. Weekly s.c. administration did not pened in practice is very close to these predictions allow a reduction in total dose [11]. Taylor et al. found ( Figure 4) . that route of administration made no difference to the rate of response, absolute reticulocyte counts and Factors affecting the response maintenance doses in 16 haemodialysis patients who completed a randomized crossover study [12] .
In the early clinical trials of r-HuEPO there was a The most recently reported trial comparing the two gratifyingly high and almost uniform response [4,5,21]. routes has given the most striking result [13] . After 6 months of i.v. treatment, the experimental subjects were switched to receive weekly s.c. r-HuEPO at onethird the weekly dose for 10 months and compared with control subjects who continued to receive r-HuEPO i.v. After this second phase, the s.c. group reverted to i.v. administration. There was no significant change in haematocrit in the experimental group during the 10 months of s.c. administration, although one patient had to revert to the i.v. route because of a drop in haematocrit. This study can, however, be criticised on the grounds that it was not randomized and 17 of the subjects failed to complete the study.
Some patients found that s.c. administration caused local pain or discomfort. Blinded comparisons from three centres showed that this was more likely with epoetin-alfa than epoetin-beta [14] [15] [16] . A change in the vehicle buffer (substituting phosphate for citrate) has solved this problem. Despite the balance of evid- reimbursement.
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The situation in clinical practice after licensing has proved rather different; 40-60% of US haemodialysis patients fail to achieve haematocrits of >30% [22] . Audit of our own unit showed that in 30% of patients, the haemoglobin concentrations were <10 g/dl ( Figure 5 ). Why should this be? The first reason is inadequate doses. There is a genuine variation in individual requirement, which may depend on red cell survival and endogenous EPO production. In clinical trials there is no constraint on increasing the dose, whereas in clinical practice each dose increment of 1000 IU/week will cost approximately an extra £500 per annum. The tendency, therefore, is to titrate the dose towards the minimum and clinicians have been very successful in this respect. Average doses are half (Figure 6 ). Figure 7 shows the large variation in the re-receiving inadequate doses; those in Panel B are probably resistant, lationship between dose and achieved haemoglobin in perhaps for reasons set out in Table 1 ; those in Panel C may be relatively resistant, requiring higher doses than average to achieve our unit. One could argue that the patients in panel A below average doses of r-HuEPO (100 IU/kg/week) which, if increased, could put them into panel C or D.
above average doses. The reasons that must be considIt is the patients in panel B who need attention for ered are shown in Table 1 . they have below average haemoglobins and they receive Iron deficiency, both absolute and relative, was recognized very early as the most important limiting factor to achieving target haemoglobin levels of 10-12 g/dl at average doses. In the US Amgen multicentre trial Eschbach found that iron deficiency was recognized in as many as 50% of cases.
Infection and inflammation, often not clinically obvious, are the next most important causes. Routine uncomplicated surgery, rejecting previously failed transplants and minor dental sepsis are examples that are commonly encountered in clinical practice. These produce a suppression of erythropoiesis which, when observed in patients with inflammatory diseases, is referred to as the 'anaemia of chronic disease'. It is explained in part by the effect of interleukin-1 (IL-1) and tumour necrosis factor ( TNF ), which act on Nephrologists sometimes fail to recognize that their patients are suffering from other blood disorders such as thalassaemia, myelofibrosis or even myeloma. Ifudu et al. have shown that under-dialysis is an independent predictor of a requirement for a higher dose of r-HuEPO [22] . The importance of this is that one can take remedial action. Aluminium intoxication is now rare but an increased load below the overtly toxic Haematocrit study will provide data on the relationship between target and achieved haematocrit and the risk of vascular access failure.
Small increases in pre-dialysis concentrations of creatinine, phosphate and potassium were observed. Apart from potassium [32] these were not usually clinically significant and probably reflected changes in diet and dialysis efficiency [4, 5, 33] . A more precise assessment of the effect of haematocrit on dialysis was conducted by Movilli et al. [34] , who showed a decrease in Kt/V in seven patients whose haematocrits rose following r-HuEPO treatment. use continue to exist for nephrologists, these are challenges to improve practice not reasons to avoid its use. range may shift the dose-response curve adversely [24] .
Conclusion
The effect of hyperparathyroidism is more controver-References sial. Rao et al. believe it has a major influence but this is not supported by others [25, 26 ] . There is only one
